



5 August 2022

(22-5846)

Page: 1/6

Committee on Market Access

Original: English

**NOTIFICATION PURSUANT TO THE DECISION ON NOTIFICATION PROCEDURES
FOR QUANTITATIVE RESTRICTIONS (G/L/59/REV.1)**

UNITED KINGDOM

Addendum

The following communication, dated 3 August 2022, is being circulated at the request of the delegation of the United Kingdom.

A. Notifying Member: United Kingdom
B. Date of notification: 3 August 2022
C. First time notification: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No, last notification was made in (doc. symbol): G/L/59/Rev.1
D. Type of notification: <input type="checkbox"/> 1. Complete (i.e. notification of all quantitative restrictions in force) <input checked="" type="checkbox"/> 2. Changes to a notification previously made in G/MA/QR/N/GBR/1 which are of the following nature: <input type="checkbox"/> 2.1 Introduction of new restrictions, as listed in Section 1. <input type="checkbox"/> 2.2 Elimination of restrictions, as described in G below. <input checked="" type="checkbox"/> 2.3 Modification of a previously notified restriction, as described in Section 1. <input type="checkbox"/> 3. Reverse notification of restrictions maintained by (Member):
E. The notification provides information for the following biennial period (e.g. 2012-2014): <u>2020-2022 and relates to restrictions in force as of 24 June 2022</u>
F. This notification contains information* relating to: <input checked="" type="checkbox"/> Section 1: List of quantitative restrictions that are currently in force. <input type="checkbox"/> Section 2: Cross-reference to other WTO notifications with information on quantitative restrictions that are currently in force and additional information.
G. Comments of a general nature, including a description of the elimination of restrictions notified under D.2.2 and the date they ceased to be in force. 1. This addendum modifies and replaces QR No. 21 of G/MA/QR/N/GBR/1. This notification updates the list of commodity codes applicable to the medicines in scope and provides further information on the product descriptions. 2. The UK is notifying the net reduction of 30 medicines from the list of medicines needed to support the treatment of UK patients at a time when COVID-19 is still having a real impact on both demand and supply of medicines, the export of which is subject to restriction in certain limited circumstances when those medicines are already in the UK supply chain and intended for UK patients.

* In English only.

-
- | |
|--|
| <p>3. These are temporary measures in place to relieve critical shortages of medicines necessary for the protection of human health. Measures are reviewed regularly and only applied where the critical need cannot be met by alternative measures. On 15 December 2021, 47 medicines were removed from the list. As of 24 June 2022, a further 32 medicines were removed from the list. Two medicines have been added to the list.</p> |
| <p>4. The UK's notification G/MA/QR/N/GBR/1 included details relating to Northern Ireland. This notification does not amend those details which continue to apply.</p> |

QR No.	General description of the restriction	Type of restriction	Tariff line code(s) affected, based on HS (2022)	Detailed Product Description	WTO Justification and Grounds for Restriction, e.g., Other International Commitments	National legal basis and entry into force	Administration, modification of previously notified measures, and other comments
	1	2	3	4	5	6	7
							of that medicine in the UK
			3004.20.00	<p><u>2. Heading 3004 - Classification</u> Medicaments consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale</p> <p><u>Product Description per Commodity Code under Heading 3004</u> Other, containing antibiotics</p>			Medicines on this list which have been produced to fulfil contracts overseas are not subject to restriction. As such, restrictions only apply to wholesaler dealer license holders that are not the market authorisation holder for a medicine intended for export. The measures are designed to ensure wholesalers fulfil their legal obligations to maintain supply to UK patients.
			3004.31.00	Other, containing hormones or other products of heading 2937 Containing insulin			These restrictions are only applied and maintained where alternative measures are not considered sufficient on their own to ensure that UK supply meets demand.
			3004.32.00	Containing corticosteroid hormones, their derivatives or structural analogues			A number of exemptions apply to medicines in scope of these restrictions. For example, exports destined for
			3004.39.00	Other			

QR No.	General description of the restriction	Type of restriction	Tariff line code(s) affected, based on HS (2022)	Detailed Product Description	WTO Justification and Grounds for Restriction, e.g., Other International Commitments	National legal basis and entry into force	Administration, modification of previously notified measures, and other comments
	1	2	3	4	5	6	7
			3004.49.00 3004.90.00	Other, containing alkaloids or derivatives thereof, Other Other Further detail of these medicines can be found at https://www.gov.uk/government/publications/medicines-that-cannot-be-parallel-exported-from-the-uk These restrictions apply in certain circumstances to exports of specified medicines which are placed on the UK market for UK patients and needed to protect human health, including to treat Covid-19, <i>inter alia</i> .			international humanitarian organisations such as COVAX are not covered. A full list of exemptions can be found at https://www.gov.uk/government/publications/medicines-that-cannot-be-parallel-exported-from-the-uk Requests for exemptions are considered on a case-by-case basis. These can be submitted by a foreign government or government agency, or a wholesaler on their behalf at restrictedmedicines@dhsc.gov.uk Further information on these measures is available here: https://www.gov.uk/guidance/parallel-export-and-boarding-of-restricted-medicines

QR No.	General description of the restriction	Type of restriction	Tariff line code(s) affected, based on HS (2022)	Detailed Product Description	WTO Justification and Grounds for Restriction, e.g., Other International Commitments	National legal basis and entry into force	Administration, modification of previously notified measures, and other comments
1	2	3	4	5	6	7	7
							<p>It is the responsibility of the wholesaler to ensure any exports are made or withheld in compliance with these restrictions. Failure to comply with these restrictions may lead to regulatory action by the Medicines and Healthcare products Regulatory Authority (MHRA) against the wholesale dealer's licence.</p> <p>There are no additional steps or declarations required from a customs perspective.</p>